The Technical Analyst
Select Language :
Aileron Therapeutics Inc [ALRN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Aileron Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Aileron Therapeutics Inc is listed at the  Exchange

-6.49% $6.63

America/New_York / 28 mar 2024 @ 16:00


Aileron Therapeutics Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 32.39 mill
EPS: -2.85
P/E: -2.33
Earnings Date: May 05, 2024
SharesOutstanding: 4.89 mill
Avg Daily Volume: 0.0397 mill
RATING 2024-03-28
B-
Sell
RATINGS
Rating CashFlow: Neutral
Return On Equity: Sell
Return On Asset: Sell
DE: Sell
P/E: Sell
Price To Book: Neutral
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/a
Ebit
Asset
Debtn/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -2.33 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.40x
Company: PE -2.33 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$1.137
(-82.85%) $-5.49
Date: 2024-03-29
Expected Trading Range (DAY)

$ 6.23 - 7.03

( +/- 6.05%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-05 Windsor James Brian Buy 2 000 Common Stock
2024-03-05 Windsor James Brian Sell 2 Series X Non-Voting Convertible Preferred
2024-02-28 Ambros Reinhard J. Buy 2 725 Stock Option (right to buy)
2024-02-28 Von Rickenbach Josef H Buy 2 725 Stock Option (right to buy)
2023-12-15 Windsor James Brian Buy 225 Common Stock
INSIDER POWER
-28.78
Last 94 transactions
Buy: 25 085 053 | Sell: 1 207 893

Forecast: 16:00 - $6.63

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $6.63
Forecast 2: 16:00 - $6.63
Forecast 3: 16:00 - $6.63
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $6.63 (-6.49% )
Volume 0.0227 mill
Avg. Vol. 0.0397 mill
% of Avg. Vol 57.17 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Aileron Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Aileron Therapeutics Inc

RSI

Intraday RSI14 chart for Aileron Therapeutics Inc

Last 10 Buy & Sell Signals For ALRN

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Aileron Therapeutics Inc

ALRN

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Last 10 Buy Signals

Date Signal @
SEIUSDMar 29 - 11:010.841
SANDUSDMar 29 - 11:01$0.707
ROSEUSDMar 29 - 11:01$0.139
UMAUSDMar 29 - 11:01$4.36
METISUSDMar 29 - 11:01$98.99
MATICUSDMar 29 - 11:01$0.998
LRCUSDMar 29 - 11:01$0.390
KAVAUSDMar 29 - 11:01$1.039
FLOWUSDMar 29 - 11:01$1.362
DIAUSDMar 29 - 11:010.689

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.